Michio Kaku: the brain “could be an open book”
Twelve years after he described a network that would carry feelings between people, Michio Kaku told Velco Dar how far the science still has to travel, and that he is certain it will arrive.
Twelve years after he described a network that would carry feelings between people, Michio Kaku told Velco Dar how far the science still has to travel, and that he is certain it will arrive.
The BCI Pioneers Coalition, a group led by people who have taken part in implanted brain-computer interface trials, published OUR BCI on 10 November 2026: participant-led recommendations in 13 areas for researchers, sponsors, manufacturers, funders, ethics boards and regulators. They cover non-disclosure agreements, ownership of implanted and external hardware and software, brain data, pay, and support after a trial ends, including the possibility of an escrow fund for implant removal. The coalition calls them a first step toward a code of practice and encourages work toward a binding one.
Cambridge, Massachusetts brain-computer interface company Axoft reported early human data from its ultra-soft Fleuron probes on 19 November 2026, from patients at Mass General Brigham and The Panama Clinic. Its first clinical target is disorders of consciousness: measuring consciousness directly in patients with severe brain injury who cannot respond. The results were presented at three conferences and have not yet appeared in a peer-reviewed journal.
PLC Neurotech Fund I LP, a Delaware venture fund based in Austin, Texas, filed a Form D with the SEC on 29 October 2026. The sole member of its general partner is Juan Benet, founder of Protocol Labs, and its adviser says it seeks to raise funds for brain-computer interfaces, neuroscience-oriented AI and connectomics. The filing showed no money raised yet and no fund size. Benet's PL Neuro programme launched a public neurotech tracker, Neuro Atlas, on 19 November.
The US Patent and Trademark Office issued US Patent 12,797,514, 'Cell-based Brain-machine Interface', to Neuralink on 17 November 2026. It describes neurons grown outside the body and laid on the surface of the cortex, where they grow into the brain and are read with a camera or electrodes and written to with light. Twelve inventors are named, among them Max Hodak and Alan Mardinly, who founded Science Corporation in 2021.
At a September FDA workshop on rare disease statistics, the FDA's background paper on device studies used brain-computer interfaces for ALS as its case example for testing devices in small populations. An FDA official said more uncertainty before approval may be acceptable when it is paired with post-market data collection, Synchron's Adam Fry said he does not think implant trials can be blinded effectively or ethically, and Paradromics said it is using its Connect-One study to design the measures for its pivotal trial.
Science Corporation, the brain-computer interface company co-founded by former Neuralink president Max Hodak, announced a $400 million Series D on 17 November 2026 from investors including Khosla Ventures, the Ackman Oxman Institute and hospital operator Tenet Healthcare. The money will widen sales of its PRIMA retinal implant in Europe and prepare a US launch through the FDA's Humanitarian Device Exemption. TechCrunch and Bloomberg reported a $3.5 billion valuation.
Brain implant researchers from UC Davis, Massachusetts General Hospital and Emory University will present at a Society for Neuroscience briefing on 17 November: a synthetic voice that captures pitch, a completely locked-in person who communicated independently for more than a year, and brain-to-text decoding that works even on an iPhone.
Precision Neuroscience and Team Gleason, the ALS charity founded by former New Orleans Saints player Steve Gleason, announced a partnership on 13 November 2026. People living with ALS, their families and caregivers will get a structured way to give feedback on Precision's brain-computer interface while it is in development, and the two will run joint education on its Layer 7 system for patients and clinicians, starting at the American Speech-Language-Hearing Association convention. Team Gleason first partnered with Synchron in 2022.
Get the latest BCI news, breakthroughs, and market moves delivered to your inbox.
No spam. One-click unsubscribe. We respect your privacy.